FLGT— Fulgent Genetics, Inc.

Health Care$528M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenue	$322.7M+13.8%	$283.5M-2.0%	$289.2M-53.3%	$619.0M
Cost of revenue	$191.8M+8.8%	$176.3M-4.6%	$184.8M-26.7%	$252.1M
Gross profit	$130.9M+22.1%	$107.2M+2.6%	$104.5M-71.5%	$366.9M
Research and development	$53.9M+10.4%	$48.8M+17.8%	$41.4M+43.3%	$28.9M
Selling and marketing	$43.4M+19.7%	$36.2M-12.6%	$41.5M+6.5%	$38.9M
General and administrative	$116.7M+32.4%	$88.1M-1.0%	$89.0M-19.9%	$111.1M
Amortization of intangible assets	$8.0M+0.8%	$8.0M+1.5%	$7.8M+20.7%	$6.5M
Goodwill impairment loss	$0	$0-100.0%	$120.2M	—
Total operating expenses	$222.0M+22.5%	$181.1M-39.6%	$300.0M+59.2%	$188.4M
Operating loss	-$91.1M-23.2%	-$73.9M+62.2%	-$195.5M-209.5%	$178.5M
Interest income	$30.9M-1.2%	$31.3M+44.8%	$21.6M+284.3%	$5.6M
Interest expense	-$75K-144.1%	$170K+134.8%	-$488K+51.8%	-$1.0M
Impairment loss	-$9.9M+1.5%	-$10.1M	—	—
Other income, net	$153K-72.7%	$561K+75.3%	$320K-63.9%	$887K
Total other income, net	$21.1M-4.1%	$22.0M+2.4%	$21.4M+290.0%	$5.5M
Loss before income taxes	-$70.0M-34.8%	-$52.0M+70.2%	-$174.1M-194.6%	$184.0M
(Benefit from) provision for income taxes	-$8.4M-3.2%	-$8.1M-805.0%	$1.2M-97.3%	$42.1M
Net loss from consolidated operations	-$61.6M-40.6%	-$43.8M+75.0%	-$175.2M-223.5%	$141.9M
Net loss attributable to noncontrolling interests	$1.1M+0.5%	$1.1M-85.0%	$7.4M+400.9%	$1.5M
Net loss attributable to Fulgent	-$60.5M-41.7%	-$42.7M+74.6%	-$167.8M-217.0%	$143.4M
Basic	-$2K-39.7%	-$1K+75.0%	-$6K-218.3%	$5K
Diluted	-$2K-39.7%	-$1K+75.0%	-$6K-221.6%	$5K
Basic	$30.8M+1.8%	$30.2M+1.5%	$29.8M-1.0%	$30.1M
Diluted	$30.8M+1.8%	$30.2M+1.5%	$29.8M-3.8%	$31.0M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 16 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.